TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34383511

Group type: EXPERIMENTAL
Intervention: Training middle managers to enact psychosocial safety climate (PSC) in work units for 8 months.
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Training middle managers to enact PSC in work units.
Number of subjects: 531

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 531
Study: 32543876

Group type: EXPERIMENTAL
Intervention: Manual Physical Therapy (MPT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional Pharmacologic Treatment (CPT)
Number of subjects: 47
Study: 34720019

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg) tablet given twice a day for two months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine added to the culture medium during IVF (PCO-clonidine group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine added to the culture medium during IVF (egg donors-clonidine group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine added to the culture medium during IVF (PCO-without group)
Number of subjects: 80
Study: 35025153

Group type: EXPERIMENTAL
Intervention: EA + biofeedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 60
Study: 33682556

Group type: EXPERIMENTAL
Intervention: ZSP1601 (25 to 350 mg single ascending dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ZSP1601 (50 or 100 mg QD multiple ascending doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ZSP1601 (100 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32274634

Group type: EXPERIMENTAL
Intervention: GM-CSF (2 ng/ml)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 422
Study: 616788547

Group type: EXPERIMENTAL
Intervention: Exercise + L-carnitine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise + Omega-3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise + Omega-3 + L-carnitine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: L-carnitine + Omega-3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise + Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 36300997

Group type: EXPERIMENTAL
Intervention: Web-based genital hygiene education
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 34463631

Group type: EXPERIMENTAL
Intervention: Electronic authentication strategies
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Manual authentication strategies
Number of subjects: 624
Study: 32445969

Group type: EXPERIMENTAL
Intervention: Cyclist positioned closer to the centre of the lane with a shorter time gap to the oncoming vehicle (6 seconds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclist positioned further from the centre of the lane with a longer time gap to the oncoming vehicle (9 seconds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female drivers' overtaking strategy
Number of subjects: 0
Study: 35065662

Group type: EXPERIMENTAL
Intervention: Single dose of intravenous (IV) phenobarbital (7.5 mg/kg of ideal body weight)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Single dose of matching IV placebo
Number of subjects: 39
Study: 32769633

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 0
Study: 35195752

Group type: EXPERIMENTAL
Intervention: Coordinator-based intervention (Liaison Intervention - LI)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-Liaison Intervention (non-LI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Secondary fractures
Number of subjects: 141
Study: 35038578

Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Cold biopsy forceps (CBF)
Number of subjects: 123
Study: 32584426

Group type: EXPERIMENTAL
Intervention: adavosertib (SUKSES-C)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: vistusertib (SUKSES-D)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: adavosertib (SUKSES-N1)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: AZD2811NP (SUKSES-N3)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (SUKSES-C and SUKSES-N1)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (SUKSES-D)
Number of subjects: 286
Study: 35099501

Group type: EXPERIMENTAL
Intervention: FDA-authorized instructions
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Intervention instructions (decision science principles)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control (no instructions)
Number of subjects: 338
Study: 34400314

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose ICS without use of background controller
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: As-needed ICS dosing
Number of subjects: 0
Study: 33549081

Group type: EXPERIMENTAL
Intervention: Overminus lenses of -2.50 D with 2 PD base-in prisms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 60
Study: 32912290

Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg BID)
Number of subjects: 132
Study: 33487257

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300 g/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular yogurt (300 g/d)
Number of subjects: 44
Study: 34080761

Group type: EXPERIMENTAL
Intervention: Reciprocal Imitation Training (RIT)
Number of subjects: 66
Study: 34978712

Group type: EXPERIMENTAL
Intervention: Cognitive intervention with strength framing
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention with strength framing
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Cognitive intervention with weakness framing
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention with weakness framing
Number of subjects: 616
Study: 33714703

Group type: EXPERIMENTAL
Intervention: Regular dressing group (RD) - dressings changed every week regularly and additionally when oozing was noticed.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Non-regular dressing group (ND) - dressings changed only when oozing was visible.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Regular dressing group (RD)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Non-regular dressing group (ND)
Number of subjects: 197
Study: 32607569

Group type: EXPERIMENTAL
Intervention: Early oral hydration (ice chips and water) after extubation
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care (a 6-hour fast)
Number of subjects: 149
Study: 35498440

Group type: EXPERIMENTAL
Intervention: Testosterone (10 mg/day)
Number of subjects: 48
Study: 33118535

Group type: EXPERIMENTAL
Intervention: Family history of cancer (FHC)
Number of subjects: 3455

Group type: COMPARATOR
Intervention: No family history of cancer (NFHC)
Number of subjects: 3455
Study: 35377708

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 750

Group type: COMPARATOR
Intervention: No maintenance (observation)
Number of subjects: 750
Study: 32160826

Group type: EXPERIMENTAL
Intervention: Bright white light
Number of subjects: 112

Group type: COMPARATOR
Intervention: Dim white light
Number of subjects: 112

Group type: COMPARATOR
Intervention: Red light
Number of subjects: 112

Group type: COMPARATOR
Intervention: Blue light
Number of subjects: 112
Study: 36293902

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual Care (controls)
Number of subjects: 97
Study: 34872283

Group type: EXPERIMENTAL
Intervention: 0.05 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.1 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline combined with sevoflurane
Number of subjects: 90
Study: 34215501

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus tailored exercise training (foam dressing, short-stretch bandage, stretching, resistive, and aerobic exercise sessions, 3 days/week for 12 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional treatment alone (foam dressing, short-stretch bandage)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus tailored exercise training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 24
Study: 33849113

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis combined with levocarnitine
Number of subjects: 75
Study: 35757205

Group type: EXPERIMENTAL
Intervention: Climbing (n = 26)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nordic walking (n = 19)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Social contact control (n = 21)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Climbing and Nordic walking
Number of subjects: 66
Study: 32198520

Group type: COMPARATOR
Intervention: Brief telephone advice (BA)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Text messages (TM)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy (NRT)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: TM + NRT
Number of subjects: 153

Group type: COMPARATOR
Intervention: BA
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: TM
Number of subjects: 153
Study: 34304487

Group type: EXPERIMENTAL
Intervention: Brandt-Daroff training combined with otolith reposition instrument
Number of subjects: 110

Group type: COMPARATOR
Intervention: Otolith reposition and health education (Control)
Number of subjects: 110
Study: 36154908

Group type: EXPERIMENTAL
Intervention: 300 mg CBD Isolate
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 300 mg CBD Broad Spectrum
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 150
Study: 33707768

Group type: EXPERIMENTAL
Intervention: Mendelian randomization applied to quantitative traits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic investigations of biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein drug targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic epidemiological studies
Number of subjects: 0
Study: 32347209

Group type: EXPERIMENTAL
Intervention: Self-healing training
Number of subjects: 34
Study: 35722465

Group type: EXPERIMENTAL
Intervention: rCCK96‐104PE38 targeted drug
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oxaliplatin
Number of subjects: 80
Study: 34533039

Group type: EXPERIMENTAL
Intervention: Glutathione infusion (2500 mg/25 mL over 10 minutes, followed by the same doses at 24, 48, and 72 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34243733

Group type: EXPERIMENTAL
Intervention: Selective caries removal
Number of subjects: 623

Group type: COMPARATOR
Intervention: Complete caries removal
Number of subjects: 623
Study: 32487243

Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude (HVLA) lumbar manipulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simulated manipulation (Control)
Number of subjects: 24
Study: 35531796

Group type: EXPERIMENTAL
Intervention: PN-HPT® (4 ml intradermally)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid (2 ml subdermally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (4 ml intradermally)
Number of subjects: 20
Study: 33244605

Group type: EXPERIMENTAL
Intervention: Food crop diversity
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Proximity to markets
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Women's salaried employment
Number of subjects: 880
Study: 32909076

Group type: EXPERIMENTAL
Intervention: ebselen (600 mg bd)
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 35686561

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg once daily for 16 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 135
Study: 33453418

Group type: EXPERIMENTAL
Intervention: liraglutide (GLP-1 analogue)
Number of subjects: 37

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study: 32414331

Group type: EXPERIMENTAL
Intervention: PIKKO (supportive care intervention including patient navigator, oncological knowledge database, specialized oncological counseling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIKKO (supportive care intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 33608976

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for adolescents + brief cognitive intervention to decrease self-criticism
Number of subjects: 40
Study: 32866634

Group type: EXPERIMENTAL
Intervention: Intralesional vitamin D3
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using eosin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 35381840

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IV group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine instillation (IP group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33740316

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) on
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) off
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cold pain threshold
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cold hyperalgesia
Number of subjects: 16
Study: 33200626

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg elemental calcium daily until 20 weeks' gestation, then 1.5 g until delivery)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 630
Study: 35829749

Group type: EXPERIMENTAL
Intervention: 166Ho TARE
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraprocedural holmium-sensitive MRI
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Treatment in MRI
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Last fraction of treatment
Number of subjects: 6
Study: 32356515

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 4.5 g, titrated to 6 or 9 g
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 6 g, increased to 9 g
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) and Modafinil
Number of subjects: 246
Study: 33280218

Group type: EXPERIMENTAL
Intervention: Laparoscopic insertion of feeding tube gastrostomy (FTG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Open surgery for feeding tube gastrostomy (FTG)
Number of subjects: 34
Study: 33667135

Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC) for 12 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 88
Study: 33684552

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (dose escalation)
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Overall Cohort (including patients from OCTAVE Induction 1 and 2, OCTAVE Sustain, and OCTAVE Open)
Number of subjects: 1139
Study: 36361460

Group type: EXPERIMENTAL
Intervention: High Machiavellianism
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Psychological capital (for female university students)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Mediation effect (for male university students)
Number of subjects: 869
Study: 35012812

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Norepinephrine 8 μg
Number of subjects: 100
Study: 32434847

Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine (9.0 × 10^5 PfSPZ)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine (4.5 × 10^5 PfSPZ)
Number of subjects: 39

Group type: COMPARATOR
Intervention: PfSPZ Vaccine (4.5 × 10^5 PfSPZ)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PfSPZ-GA1 Vaccine (both doses)
Number of subjects: 39
Study: 36102803

Group type: EXPERIMENTAL
Intervention: TENS based on wrist‐ankle acupuncture
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 34407542

Group type: EXPERIMENTAL
Intervention: asciminib 40 mg twice daily
Number of subjects: 233

Group type: COMPARATOR
Intervention: bosutinib 500 mg once daily
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: asciminib
Number of subjects: 233
Study: 32034814

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg) from Fangming Pharmaceutical Group (Test, T)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amlodipine (5 mg) from NORVASC® (Reference, R)
Number of subjects: 48
Study: 35717662

Group type: EXPERIMENTAL
Intervention: Task-specific movement program (TSM program) for 4 weeks (60 minutes per session, total of 15 sessions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Routine rehabilitation program (total of 12 sessions)
Number of subjects: 22
Study: 32222806

Group type: EXPERIMENTAL
Intervention: Statin group (36 patients)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-statin group (62 patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-statin group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 98
Study: 36348372

Group type: EXPERIMENTAL
Intervention: Early postoperative home-based strength training protocol
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard physiotherapy during hospitalization
Number of subjects: 248
Study: 34154590

Group type: EXPERIMENTAL
Intervention: Relugolix 10 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Relugolix 20 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Relugolix 40 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Leuprorelin 3.75 mg
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 32384434

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding treatment (two weeks at predefined acupuncture points: Shenshu (BL23), Sanyinjiao (SP6), Guanyuan (RN4), Ganshu (BL18), Zusanli (ST36), Pishu (BL20))
Number of subjects: 70

Group type: COMPARATOR
Intervention: Alprazolam tablet (0.4 mg, 1 tablet, 3 times a day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) and proton magnetic resonance spectroscopy (1H-MRS) scans
Number of subjects: 70
Study: 35031868

Group type: EXPERIMENTAL
Intervention: 1 L-PEG/Asc
Number of subjects: 202

Group type: COMPARATOR
Intervention: 2 L-PEG/Asc
Number of subjects: 202
Study: 34579620

Group type: EXPERIMENTAL
Intervention: Verbal consultation (VC) + HSWAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal consultation (VC) only (pre-crossover control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal consultation (VC) + HSWAP (post-crossover control)
Number of subjects: 0
Study: 33706003

Group type: EXPERIMENTAL
Intervention: Bupropion XL 300 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32559029

Group type: COMPARATOR
Intervention: MTA only
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MTA + EMP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MTA + rhPDGF
Number of subjects: 18
Study: 36001100

Group type: EXPERIMENTAL
Intervention: Tofacitinib/XR
Number of subjects: 62010

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 62010

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 62010
Study: 33038505

Group type: EXPERIMENTAL
Intervention: New waiver program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (existing Medicaid expansion program)
Number of subjects: 0
Study: 32132655

Group type: EXPERIMENTAL
Intervention: Leukapheresis
Number of subjects: 779

Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 779
Study: 33183068

Group type: EXPERIMENTAL
Intervention: PMA-zeolite-clinoptilolite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35248019

Group type: EXPERIMENTAL
Intervention: Axillary vein/subclavian vein (AxV/SCV) approach
Number of subjects: 248

Group type: COMPARATOR
Intervention: Internal jugular vein (IJV) approach
Number of subjects: 248
Study: 34654402

Group type: EXPERIMENTAL
Intervention: Radiotherapy comprising 25 Gy in 5 fractions with concomitant (150 mg/m2/day, 5 days) and adjuvant temozolomide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Radiotherapy comprising 40 Gy in 15 fractions with concomitant (75 mg/m2/day, every day from first to last day of radiation) and adjuvant temozolomide
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Radiotherapy comprising 25 Gy in 5 fractions with concomitant and adjuvant temozolomide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Radiotherapy comprising 40 Gy in 15 fractions with concomitant and adjuvant temozolomide
Number of subjects: 270
Study: 35387783

Group type: EXPERIMENTAL
Intervention: BCT plus ultrasound guided intra‐articular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: BCT plus ultrasound guided intra‐articular hip injection of 5 mL 1% lidocaine
Number of subjects: 199

Group type: COMPARATOR
Intervention: BCT (best current treatment)
Number of subjects: 199
Study: 33119332

Group type: EXPERIMENTAL
Intervention: Supportive supervisor training (SST)
Number of subjects: 250
Study: 35640099

Group type: EXPERIMENTAL
Intervention: Oral-Silent-Oral (OSO) condition
Number of subjects: 21

Group type: COMPARATOR
Intervention: Silent-Oral (SO) condition
Number of subjects: 21